Date: 2011-05-26
Type of information: Services contract
Compound: monoclonal antibody technology
Company: Bayer Schering Pharma (Germany) Epitomics (USA)
Therapeutic area:
Type agreement: Services
Action mechanism:
Disease:
Details: Bayer Schering Pharma and Epitomics have signed a service agreement. Epitomics will use its proprietary rabbit monoclonal antibody technology to produce antibodies for Bayer HealthCare's drug target identification and validation. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity, specificity and bioactivity both in vitro and in vivo.
Financial terms: Financial terms of this agreement are not disclosed.
Latest news:
